These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35232215)

  • 1. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
    Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
    J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
    Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
    Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
    Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables.
    Maki KC; Bobotas G; Dicklin MR; Huebner M; Keane WF
    J Clin Lipidol; 2017; 11(1):102-109. PubMed ID: 28391875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
    Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
    J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia.
    Dai Perrard XY; Lian Z; Bobotas G; Dicklin MR; Maki KC; Wu H
    J Clin Lipidol; 2017; 11(6):1361-1371. PubMed ID: 28942094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State.
    Maki KC; Palacios OM; Buggia MA; Trivedi R; Dicklin MR; Maki CE
    Clin Ther; 2018 Dec; 40(12):2065-2076. PubMed ID: 30454850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
    Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
    Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
    Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(3):199-207. PubMed ID: 23725919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
    Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
    JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
    Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
    Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
    Ballantyne CM; Manku MS; Bays HE; Philip S; Granowitz C; Doyle RT; Juliano RA
    Cardiol Ther; 2019 Jun; 8(1):79-90. PubMed ID: 30788718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation.
    Skulas-Ray AC; Flock MR; Richter CK; Harris WS; West SG; Kris-Etherton PM
    Nutrients; 2015 Aug; 7(8):6390-404. PubMed ID: 26247967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.